
Cochrane Database of Systematic Reviews - - Cochrane Protocol (ongoing review)

Continuous glucose monitoring systems for the diagnosis of cystic fibrosis-related diabetes

Code: CD012953

Year: 2018 **Date:** 2018

Author: Ahmed MI

Study design (if review, criteria of inclusion for studies)

Cross-sectional studies and prospective cohort studies. Randomised comparisons of tests in which all participants have been cross-classified with a reference standard will be included. Excluded: case-control studies, case reports, studies where CGMS is performed retrospectively after an abnormal OGTT.

Participants

People (both children and adults) with CF in whom cystic fibrosis-related diabetes (CFRD), as outlined by the ADA 2016 criteria, is suspected or who are being routinely screened for CFRD.

Interventions

Comparison of continuous glucose monitoring systems (CGMS) (index test) against the reference standard (diagnosis of CFRD as outlined by the ADA criteria) in the diagnosis of cystic fibrosis-related diabetes (CFRD).

Outcome measures

Accuracy of continuous glucose monitoring systems (CGMS) in detecting abnormalities of glycaemic control. The clinical reference standard is the diagnosis of CFRD as outlined by the ADA criteria

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012953/abstract>

See also

Ahmed MI, Fox R, Shinkins B, Sutton S, Tziaferi V, Gaillard EA. Continuous glucose monitoring systems for the diagnosis of cystic fibrosis-related diabetes (Protocol). Cochrane Database of Systematic Reviews 2018, Issue 2. Art. No.: CD012953. DOI: 10.1002/14651858.CD012953.

Keywords

Diabetes Mellitus; Gastrointestinal Diseases; Pancreatic Diseases; non pharmacological intervention - diagn; diagnostic procedures; Continuous glucose monitoring systems;